Multiple adalimumab biosimilars will be launching in 2023, and as biosimilar use increases in the United States, health systems and providers will encounter a new challenge: educating and switching their patients from reference product to biosimilar. Nurses play a vital role in educating patients and including them in the shared decision-making process.

This presentation will cover the basics of biosimilar development; key concepts including extrapolation, interchangeability, and immunogenicity; and clinical practice implications, including switching and the nocebo effect. There will be an overview of the disease states where biosimilars will enter the treatment landscape, along with a summary of the biosimilars landscape. Participants will build a foundation for biosimilar-related knowledge, applicable to their practice in multiple ways (especially for patient education and answering questions on switching when a biosimilar is prescribed).

CRNI® RUs: 2